MMR vaccine safety in kids after heart transplant
Part of Infections, Mouth & dental clinical trials.
This trial tests whether the MMR (measles, mumps, rubella) vaccine is safe and works well for children who have had a heart transplant. It may help protect you from these diseases if you haven't had the vaccine or no longer have immunity.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have received a heart transplant
- It has been at least 1 year since your transplant
- It has been at least 1 year since you had treatment for antibody-mediated rejection
- It has been at least 6 months since you had high-dose steroids or basiliximab
- You have never had the MMR vaccine, or you had it but now lack protection against measles
- You are generally feeling well and healthy
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well adults stay protected against measles after they receive a donor bone marrow transplant. It helps doctors understand measles immune status and may guide future protection for transplant recipients.
This trial studies whether belatacept can be used after a heart transplant to help protect kidney function over time. It focuses on people who already have (or are at risk for) worsening kidney function after transplant, while avoiding those with certain infections or rejection concerns.
This study tests whether a drug called belatacept can safely help your body accept a new heart without rejecting it, and may reduce the need for other strong immune-suppressing medicines. If you are getting a heart transplant for the first time and have certain immune markers, this trial may be an option for you.
This trial tests whether Thymoglobulin® is safe and how well it works in people getting their first heart transplant. It may help doctors fine-tune medicines used to prevent the body from rejecting the new heart.
This trial checks whether using heart-monitoring blood tests and biopsy results can help customize (optimize) immune-suppression medication soon after your transplant. It aims to keep the transplanted heart safe while avoiding over- or under-treatment.
This trial studies whether belatacept, an anti-rejection medicine given by IV, can work for people receiving their first heart transplant. It aims to see if it prevents rejection safely for patients and whether it fits better than standard approaches for certain candidates.
Hear when a new Heart Transplant Infection Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.